Why You Don't Need to Cycle CJC-1295 or Tesamorelin
Your pituitary gland has two completely separate receptor systems for releasing growth hormone, and the cycling advice you see online almost never makes that distinction.
The first system responds to something called growth hormone releasing hormone, or GHRH, which is the signal your hypothalamus sends when it wants the pituitary to release growth hormone. The second system responds to something called ghrelin, which is a hunger-related hormone that also has a secondary role in triggering growth hormone release. These two receptor systems sit on the same pituitary cells, they produce the same downstream output, but they are independent pathways that do not interfere with each other and do not behave the same way under continuous stimulation.
That distinction is the whole mechanism behind when cycling matters and when it does not.
CJC-1295 and tesamorelin work through the GHRH receptor. Ipamorelin works through the ghrelin receptor. When you buy a combined vial of CJC and Ipamorelin, you are stimulating both systems at once, and that is where most people get confused, because the cycling advice that comes with that vial applies to the two compounds as if they are one thing.
They are not.
To understand why one system desensitizes and the other does not, you need to know what desensitization actually means at the receptor level. When a receptor gets stimulated repeatedly or continuously, cells have a built-in mechanism to reduce their sensitivity to that signal, and one of the primary ways they do this is by physically removing receptors from the cell surface through a process called beta-arrestin mediated internalization, which is essentially the cell pulling its own antennas down into the interior of the cell where the signal can no longer reach them. Fewer surface receptors means a weaker response to the same amount of stimulation, even if the stimulation itself has not changed.
This is what happens with ghrelin receptors under continuous stimulation.
A 16-week human trial tracked growth hormone response in subjects receiving continuous ghrelin receptor stimulation and found that the response declined approximately 45 percent from baseline by week 16. When subjects stopped for four weeks, the response returned completely to where it had started. That is not a partial recovery. That is full restoration, which tells you the internalization is reversible and the receptor population does regenerate, it just needs time off the signal to do so.
This is why you cycle Ipamorelin. Three months on, one month off is the standard pattern derived from that kind of recovery window.
Now here is where GHRH receptors behave differently.
Tesamorelin was administered daily in Phase 3 clinical trials for 52 consecutive weeks, and IGF-1 levels, which are the downstream marker for sustained growth hormone activity, held steady across the entire 52-week period with no measurable decline. That is more than a year of daily dosing without receptor blunting.
The reason GHRH receptors do not undergo the same degree of internalization comes down to the half-life of the signal. Tesamorelin has a plasma half-life of approximately 26 to 38 minutes. You inject it, it binds the receptor, it triggers a pulse of growth hormone release, and then it is cleared from the system before the next natural pulsatile window. So the receptor gets a brief, sharp stimulus followed by roughly 23 or more hours of recovery time before the next dose arrives. That recovery window appears to be sufficient to prevent the kind of sustained receptor occupancy that drives internalization.
Ghrelin receptors under a typical Ipamorelin dosing protocol, which often involves multiple injections per day, do not get the same extended recovery window. The receptor is seeing signal more frequently and for longer cumulative periods, and that sustained occupancy is what drives the beta-arrestin pathway and starts pulling receptors off the surface.
A 1991 study using perifused rat pituitary cells directly tested whether stimulating one of these systems could cause cross-desensitization in the other, meaning whether running Ipamorelin could blunt your GHRH receptors or vice versa. It found no cross-desensitization at all. The systems are independent. What happens at the ghrelin receptor stays at the ghrelin receptor, and the GHRH receptor is unaffected.
This has a direct practical implication for how you think about stacked protocols.
If you are running CJC-1295 or tesamorelin alongside Ipamorelin and you cycle the combination, you are cycling because of the Ipamorelin. The GHRH side of that protocol does not require a cycle break. The cycling rule belongs to the ghrelin receptor component.
And if you are running tesamorelin by itself, there is no published evidence that demonstrates a need to cycle it at all. The 52-week Phase 3 data shows uninterrupted IGF-1 elevation without tachyphylaxis. The NEJM trial published in 2007 showed the same sustained effect at 26 weeks. There is no data in either direction suggesting the GHRH receptor system desensitizes on a clinically meaningful timescale with once-daily pulsatile dosing.
It is worth noting that the ghrelin receptor story is more nuanced even than the 45 percent decline figure suggests. A two-year study using MK-677, which is an oral ghrelin mimetic that works through the same receptor system as Ipamorelin, found that GH and IGF-1 levels remained elevated above baseline for the full two years of continuous use, though at a lower magnitude than the initial response. So the internalization does not mean the receptor becomes completely unresponsive. It means you are leaving response on the table relative to what a fresh receptor population could produce, and a break restores that capacity.
The practical approach is straightforward. Run tesamorelin continuously if your protocol calls for it. If you are stacking it with a ghrelin agonist like Ipamorelin or MK-677, structure the cycle break around the ghrelin agonist, not around the GHRH analog.
Most people are told to cycle everything because that is the safest blanket recommendation when you do not understand which part of the system is actually creating the tolerance. But receptor systems are specific, the mechanisms that drive desensitization are specific, and the recovery protocols should match the actual biology rather than treating every peptide like it operates through the same pathway.
They do not, and the 52-week data makes that plain.
References
- Rahim A, Shalet SM. Does desensitization to hexarelin occur? Growth Horm IGF Res. 1998;8 Suppl B:141-143 — 16-week human trial showing 45% GH response decline with continuous ghrelin receptor stimulation, full recovery after 4 weeks off. Source
- Falutz J et al. Metabolic effects of a growth hormone-releasing factor in patients with HIV. NEJM. 2007 — Tesamorelin daily dosing for 26 weeks with sustained IGF-1 elevation. Source
- FDA Prescribing Information. EGRIFTA (tesamorelin). 2010/2025 — 52-week pooled Phase 3 data showing sustained IGF-1 and VAT reduction through week 52
- Blake AD, Smith RG. Desensitization studies using perifused rat pituitary cells. J Endocrinol. 1991;1291:11-19 — Proved GHRH and ghrelin receptor systems are independent with no cross-desensitization. Source
- Nass R et al. Effects of an oral ghrelin mimetic on body composition in healthy older adults. Ann Intern Med. 2008;1499:601-611 — MK-677 ghrelin mimetic maintained GH/IGF-1 elevation for 2 years of continuous use. Source
Join the free community:
Men: Iron Forge Brotherhood
Women: Powerhouse Fitness
If this is the kind of information you want access to on a daily basis, the community is free and there are full courses on training, nutrition, hormones, and supplementation inside. You can ask questions and post your own labs and get feedback from me and from the community.